Ascendis Pharma A (ASND) Return on Invested Capital (2021 - 2026)
Ascendis Pharma A (ASND) posted Return on Invested Capital of 0.0% for Q1 2026, up 75.21% sequentially from 0.0% in Q4 2025, and down 102.0% YoY from 0.0% in Q1 2025.
Ascendis Pharma A (ASND) Return on Invested Capital (2021 - 2026) Analysis & Trends
Ascendis Pharma A has reported Return on Invested Capital for 6 years, with the latest figure at 0.0% in Q1 2026.
- Quarterly Return on Invested Capital fell 102.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (down 102.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital advanced to 0.0% in Q1 2026 per ASND's latest filing, from 0.0% in the prior quarter.
- Over five years, Return on Invested Capital peaked at 1.12% in Q4 2024 and troughed at 0.01% in Q1 2022.
- A 5-year average of 0.23% and a median of 0.0% in 2024 frame the typical range for Return on Invested Capital.
- The sharpest annual moves came in 2024 and 2025: Return on Invested Capital jumped 112 bps in 2024, then sank 112 bps in 2025.
- Over 5 years, Return on Invested Capital stood at 0.0% in 2022, then fell by 2 bps to 0.0% in 2023, then soared by 34484 bps to 1.12% in 2024, then plunged by 100 bps to 0.0% in 2025, then jumped by 75 bps to 0.0% in 2026.
- According to Business Quant data, Return on Invested Capital over the past three periods registered 0.0%, 0.0%, and 0.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.86% |
| Jun 30, 2025 | 0.92% |
| Mar 31, 2025 | 1.02% |
| Dec 31, 2024 | 1.12% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.05% |
| Sep 30, 2021 | -0.05% |
| Jun 30, 2021 | -0.05% |